China revising GMPs

China is expected to enact a new version of its good manufacturing practices to ensure the quality and safety of national medicines. Future production will need to follow the revised GMP standards, says China Financial Daily.

The State Food and Drug Administration says it will focus on the new standards, especially for essential medicines--those required for basic healthcare needs and that are available to the public at all times and in adequate amounts. These drugs are included in a list published for the first time and expected to be updated annually, according to China Knowledge.

To meet the new standards, some facilities and manufacturing processes may require re-inspection.

- here's the Financial Daily report
- read the China Knowledge item

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.